Following adjustment for all covariates, a 19% decreased risk was noted among PR+ patients with BC-LuC (HR = 0.81, 95% CI: 0.71–0.93, p = 0.002), while HER2+ patients exhibited a 17% lower risk (HR = 0.83, 95% CI: 0.72–0.96, p = 0.012, Table 2). This evidence concerns the gene ERBB2 and breast cancer.